Xiaolong Yan

Government of the People's Republic of China - Sixth Medical Center

Government of the People's Republic of China - Department of Thoracic Surgery

SCHOLARLY PAPERS

1

DOWNLOADS

4

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Aumolertinib Plus Apatinib Versus Aumolertinib in Untreated, EGFR-Mutant, Advanced NSCLC (ATTENTION): A Randomized, Multi-Center, Phase 2 Study

Number of pages: 27 Posted: 15 Apr 2025
Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Clinical Oncology, Government of the People's Republic of China - Department of Thoracic Surgery, Government of the People's Republic of China - Sixth Medical Center, Government of the People's Republic of China - Department of Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University, Central South University - Thoracic Medicine Department II, Zhengzhou University - Henan Provincial People's Hospital, Qingdao University - Affiliated Hospital, Changzhi City People's Hospital, Government of the People's Republic of China - Fourth Medical Center, Government of the People's Republic of China - Seventh Medical Center, Government of the People's Republic of China - Air Force Medical Center, Beijing Fengtai YouAnMen Hospital, Huazhong University of Science and Technology, Wuhan University - Renmin Hospital, Burning Rock Biotech, China Medical University, China Medical University, China Medical University, Burning Rock Biotech - Department of Medicine, Government of the People's Republic of China - Department of Oncology and Independent
Downloads 4 (1,303,821)

Abstract:

Loading...

Aumolertinib, EGFR, apatinib, VEGFR, NSCLC